Clinical utility of viscoelastic testing in chronic liver disease: A systematic review

Table 1 Rebalanced haemostasis in chronic liver disease

	Procoagulant factors	Anticoagulant factors
Primary haemostasis	Increased vWF	Thrombocytopenia
	Reduced ADAMTS13	+/- platelet dysfunction
Secondary haemostasis/coagulation	High FVIII	Reduced synthesis of FII, FV, FVII, FIX and FXI
	Reduced protein C, protein S and antithrombin
		Dysfibrinogenaemia
		Low fibrinogen (in end stage disease)
Fibrinolysis	Low plasminogen	Low antiplasmin
		Low TAFI
	High PAI-1	High tPA

ADAMTS13: A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; PAI-1: Plasminogen activator inhibitor-1; TAFI: Thrombin-activatable fibrinolysis inhibitor; tPA: Tissue plasminogen activator; vWF: von Willebrand factor.